Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety

BACKGROUND: Triple negative breast cancer (TNBC) is clinically aggressive breast cancer with a poor prognosis. Approximately 20% of TNBC has been found to express programmed death ligand 1 (PD-L1), making it a potential therapeutic target. As a PD-L1 inhibitor, atezolizumab is a recently approved im...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharmni Vishnu, K., Win, Thin Thin, Aye, Saint Nway, Basavaraj, Arun Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637314/
https://www.ncbi.nlm.nih.gov/pubmed/36335316
http://dx.doi.org/10.1186/s12885-022-10225-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637314/
https://www.ncbi.nlm.nih.gov/pubmed/36335316
http://dx.doi.org/10.1186/s12885-022-10225-y

Ejemplares similares